Tagged with Diabetes

Cell & Gene Therapy The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s quest for knowledge, costing USD three billion across 13 years. But even after nearly two decades, we have barely scratched…

UAE Dr Emran Khan, an endocrinologist at King’s College Hospital Dubai, provides an overview of the prevalence of diabetes in the UAE after studies revealed that around 17 percent of the population suffers from the disease. Moreover, Dr Khan analyzes the country’s efforts to combat the disease and the role that…

Romania Cecilia Radu of Novo Nordisk Romania shares her tumultuous four years that have seen declining market share and have culminated in launching the company’s first new product onto the market in several years. She reveals that the perception of diabetes in Romania is skewed, as more than 50 percent of…

Romania Attila Fejer general manager of Eli Lilly in Romania gives his insights on the “deadly cocktail” of challenging policies that govern the pharmaceutical industry in the country. He shares the new therapeutic direction that Lilly has taken by moving into rheumatology and dermatology. Additionally, he points to the change in…

Romania Norina Alinta Gavan, CEO of Wörwag Pharma Romania, reveals how the affiliate will become more active and entrepreneurial with the change in shareholding while having an increased responsibility for the group. She shares her insights on how her team has contributed to Wörwag’s consistent success, and how it has gained…

UAE Growing incidence of lifestyle-related diseases, coupled with high drug prices, are driving up healthcare costs at astounding rates in the Middle East and North Africa, with experts urging preventative measures to reverse the trend.   Healthcare costs in the Gulf region are expected to rise at a greater rate than…

Hungary Calin Galaseanu, recently appointed general manager of Novo Nordisk Hungary, elaborates on the country’s strong treatment paradigm for diabetes. He goes on to highlight Hungary’s key positioning as a strategic affiliate for Novo Nordisk in the areas of market access success and clinical trial capabilities.     Hungary is actually…

Puerto Rico In Puerto Rico, approximately 16 percent of the adult population has diabetes, one the highest prevalence in the world, compared to 10 percent in the general US population. As a result, diabetes represents a significant burden to the local healthcare system and population.   To tackle the rise of diabetes,…

Czech Republic Jan Škrha, president of the Czech Diabetes Society (ČDS), provides insight into the most crucial advances in the quality care of Diabetes, which relies on the indispensable cooperation between specialists and General Practitioners (GPs). Škrha puts a strong emphasis on the importance of early diagnosis and discusses the underestimated role…

China The rate of diabetes in China has exploded: the number of diabetic patients has surpassed 100 million and is expected to increase to 150 million by 2040. Dr Qinghua Wang, founder and CEO of Innogen, returned to China in 2014 with the hope of tackling this disease with Diabegone, an…

UAE The UAE’s rapid economic growth over the last half-century has been accompanied by a surge in lifestyle diseases such as diabetes and obesity. Both public and private organizations are now stepping up to tackle this health and economic burden with expanded access to cutting-edge treatments, a greater focus on education…

Thailand Every generation of Novo Nordisk’s insulin portfolio is currently on the Thai Market and the affiliate is one of the fastest-growing pharma multinationals in Thailand. Upon this solid foundation, Novo is now looking to bring the company’s latest and most innovative products to Thailand, branch out into obesity treatments, and…